97 related articles for article (PubMed ID: 26920791)
1. Use of antibodies neutralizing epithelial cell infection to diagnose patients at risk for CMV Disease after transplantation.
Blanco-Lobo P; Cordero E; Martín-Gandul C; Gentil MA; Suárez-Artacho G; Sobrino M; Aznar J; Pérez-Romero P
J Infect; 2016 May; 72(5):597-607. PubMed ID: 26920791
[TBL] [Abstract][Full Text] [Related]
2. Viral load, CMV-specific T-cell immune response and cytomegalovirus disease in solid organ transplant recipients at higher risk for cytomegalovirus infection during preemptive therapy.
Martín-Gandul C; Pérez-Romero P; Blanco-Lobo P; Benmarzouk-Hidalgo OJ; Sánchez M; Gentil MA; Bernal C; Sobrino JM; Rodríguez-Hernández MJ; Cordero E;
Transpl Int; 2014 Oct; 27(10):1060-8. PubMed ID: 24964364
[TBL] [Abstract][Full Text] [Related]
3. Role of cytomegalovirus (CMV)-specific polyfunctional CD8+ T-cells and antibodies neutralizing virus epithelial infection in the control of CMV infection in an allogeneic stem-cell transplantation setting.
Giménez E; Blanco-Lobo P; Muñoz-Cobo B; Solano C; Amat P; Pérez-Romero P; Navarro D
J Gen Virol; 2015 Sep; 96(9):2822-2831. PubMed ID: 26025872
[TBL] [Abstract][Full Text] [Related]
4. CMV-specific T-cell immunity in solid organ transplant recipients at low risk of CMV infection. Chronology and applicability in preemptive therapy.
Mena-Romo JD; Pérez Romero P; Martín-Gandul C; Gentil MÁ; Suárez-Artacho G; Lage E; Sánchez M; Cordero E
J Infect; 2017 Oct; 75(4):336-345. PubMed ID: 28599954
[TBL] [Abstract][Full Text] [Related]
5. Quantitative analysis of neutralizing antibody response to human cytomegalovirus in natural infection.
Wang D; Li F; Freed DC; Finnefrock AC; Tang A; Grimes SN; Casimiro DR; Fu TM
Vaccine; 2011 Nov; 29(48):9075-80. PubMed ID: 21945962
[TBL] [Abstract][Full Text] [Related]
6. [Monitoring of cytomegalovirus-specific CD4+ and CD8+ T cell responses by cytokine flow cytometry in renal transplant recipients].
Kılınçkaya Doğan H; Mutlu E; Köksoy S; Yılmaz VT; Koçak H; Çolak D; Mutlu D; Günseren F; Dinçkan A; Aliosmanoğlu İ; Süleymanlar G; Gültekin M
Mikrobiyol Bul; 2016 Apr; 50(2):224-35. PubMed ID: 27175495
[TBL] [Abstract][Full Text] [Related]
7. Going beyond serology for stratifying the risk of CMV infection in transplant recipients.
Navarro D; Fernández-Ruiz M; Aguado JM; Sandonís V; Pérez-Romero P
Rev Med Virol; 2019 Jan; 29(1):e2017. PubMed ID: 30358016
[TBL] [Abstract][Full Text] [Related]
8. Impact of pretransplant CMV-specific T-cell immune response in the control of CMV infection after solid organ transplantation: a prospective cohort study.
Molina-Ortega A; Martín-Gandul C; Mena-Romo JD; Rodríguez-Hernández MJ; Suñer M; Bernal C; Sánchez M; Sánchez-Céspedes J; Pérez Romero P; Cordero E
Clin Microbiol Infect; 2019 Jun; 25(6):753-758. PubMed ID: 30292792
[TBL] [Abstract][Full Text] [Related]
9. Human cytomegalovirus (HCMV)-specific T cell but not neutralizing or IgG binding antibody responses to glycoprotein complexes gB, gHgLgO, and pUL128L correlate with protection against high HCMV viral load reactivation in solid-organ transplant recipients.
Lilleri D; Zelini P; Fornara C; Zavaglio F; Rampino T; Perez L; Gabanti E; Gerna G
J Med Virol; 2018 Oct; 90(10):1620-1628. PubMed ID: 29797330
[TBL] [Abstract][Full Text] [Related]
10. Effect of long-term prophylaxis in the development of cytomegalovirus-specific T-cell immunity in D+/R- solid organ transplant recipients.
San-Juan R; Navarro D; García-Reyne A; Montejo M; Muñoz P; Carratala J; Len O; Fortun J; Muñoz-Cobo B; Gimenez E; Eworo A; Sabe N; Meije Y; Martín-Davila P; Andres A; Delgado J; Jimenez C; Amat P; Fernández-Ruiz M; López-Medrano F; Lumbreras C; Aguado JM;
Transpl Infect Dis; 2015 Oct; 17(5):637-46. PubMed ID: 26134282
[TBL] [Abstract][Full Text] [Related]
11. RT-qPCR-based microneutralization assay for human cytomegalovirus using fibroblasts and epithelial cells.
Wang X; Peden K; Murata H
Vaccine; 2015 Dec; 33(51):7254-7261. PubMed ID: 26552003
[TBL] [Abstract][Full Text] [Related]
12. High levels of CMV-IE-1-specific memory T cells are associated with less alloimmunity and improved renal allograft function.
Nickel P; Bold G; Presber F; Biti D; Babel N; Kreutzer S; Pratschke J; Schönemann C; Kern F; Volk HD; Reinke P
Transpl Immunol; 2009 Mar; 20(4):238-42. PubMed ID: 19032982
[TBL] [Abstract][Full Text] [Related]
13. Pretransplant CD8 T-cell response to IE-1 discriminates seropositive kidney recipients at risk of developing CMV infection posttransplant.
López-Oliva MO; Martinez V; Buitrago A; Jiménez C; Rivas B; Escuin F; Santana MJ; Selgas R; Bellón T
Transplantation; 2014 Apr; 97(8):839-45. PubMed ID: 24345896
[TBL] [Abstract][Full Text] [Related]
14. Dynamics and Clinical Significance of Cytomegalovirus-Specific Neutralizing Antibodies in Kidney Transplant Recipients Treated with T-Cell-Depleting Agents.
Fernández-Ruiz M; García-Ríos E; Redondo N; Rodríguez-Goncer I; Ruiz-Merlo T; Parra P; Sandonis V; López-Medrano F; San Juan R; González E; Polanco N; Andrés A; Navarro D; Aguado JM; Pérez-Romero P
J Infect Dis; 2024 Jun; 229(6):1812-1816. PubMed ID: 37740549
[TBL] [Abstract][Full Text] [Related]
15. Utility of the Enzyme-Linked Immunospot Interferon-γ-Release Assay to Predict the Risk of Cytomegalovirus Infection in Hematopoietic Cell Transplant Recipients.
Nesher L; Shah DP; Ariza-Heredia EJ; Azzi JM; Siddiqui HK; Ghantoji SS; Marsh LY; Michailidis L; Makedonas G; Rezvani K; Shpall EJ; Chemaly RF
J Infect Dis; 2016 Jun; 213(11):1701-7. PubMed ID: 26908740
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of cytomegalovirus (CMV)-specific T-cell immunity for the assessment of the risk of active CMV infection in non-immunosuppressed surgical and trauma intensive care unit patients.
Clari MA; Aguilar G; Benet I; Belda J; Giménez E; Bravo D; Carbonell JA; Henao L; Navarro D
J Med Virol; 2013 Oct; 85(10):1802-10. PubMed ID: 23868746
[TBL] [Abstract][Full Text] [Related]
17. Pre-transplant assessment of CMV-specific immune response by Elispot assay in kidney transplant recipients.
Rittà M; Costa C; Sidoti F; Ballocco C; Ranghino A; Messina M; Biancone L; Cavallo R
New Microbiol; 2015 Jul; 38(3):329-35. PubMed ID: 26147141
[TBL] [Abstract][Full Text] [Related]
18. Optimization of interferon gamma ELISPOT assay to detect human cytomegalovirus specific T-cell responses in solid organ transplants.
Abate D; Saldan A; Forner G; Tinto D; Bianchin A; Palù G
J Virol Methods; 2014 Feb; 196():157-62. PubMed ID: 24216234
[TBL] [Abstract][Full Text] [Related]
19. Quantiferon-CMV test in prediction of cytomegalovirus infection after kidney transplantation.
Lochmanova A; Lochman I; Tomaskova H; Marsalkova P; Raszka J; Mrazek J; Dedochova J; Martinek A; Brozmanova H; Grundmann M
Transplant Proc; 2010 Nov; 42(9):3574-7. PubMed ID: 21094818
[TBL] [Abstract][Full Text] [Related]
20. Monitoring cytomegalovirus T-cell immunity in small bowel/multivisceral transplant recipients.
Chiereghin A; Gabrielli L; Zanfi C; Petrisli E; Lauro A; Piccirilli G; Baccolini F; Dazzi A; Cescon M; Morelli MC; Pinna AD; Landini MP; Lazzarotto T
Transplant Proc; 2010; 42(1):69-73. PubMed ID: 20172283
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
